Clinical Trial Update: Lutropin Alfa in Women at Risk of Poor Response [Phase 2]

View source ↗

Summary

Phase 2 trial update on Lutropin Alfa for women at risk of poor ovarian response completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Stimulation

Drugs mentioned

• Lutropin alfa (lutropin alfa)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Ovarian Stimulation | Phase 2 | Status: COMPLETED | Results posted: 2018-07-30